MiNK Therapeutics (INKT) Competitors

MiNK Therapeutics logo
$9.28 -0.07 (-0.75%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$9.30 +0.02 (+0.16%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

INKT vs. FTFT, RNAC, ELDN, PYXS, and BBOT

Should you buy MiNK Therapeutics stock or one of its competitors? MiNK Therapeutics's main competitors and comparable companies include Future FinTech Group (FTFT), Cartesian Therapeutics (RNAC), Eledon Pharmaceuticals (ELDN), Pyxis Oncology (PYXS), and BridgeBio Oncology Therapeutics (BBOT). Companies are selected based on similarities in market, industry, and size.

How does MiNK Therapeutics compare to Future FinTech Group?

MiNK Therapeutics (NASDAQ:INKT) and Future FinTech Group (NASDAQ:FTFT) are related small-cap companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Future FinTech Group shares are held by institutional investors. 20.4% of MiNK Therapeutics shares are held by company insiders. Comparatively, 0.0% of Future FinTech Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, MiNK Therapeutics had 13 more articles in the media than Future FinTech Group. MarketBeat recorded 15 mentions for MiNK Therapeutics and 2 mentions for Future FinTech Group. Future FinTech Group's average media sentiment score of 0.57 beat MiNK Therapeutics' score of 0.53 indicating that Future FinTech Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MiNK Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Future FinTech Group
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

MiNK Therapeutics has a net margin of 0.00% compared to Future FinTech Group's net margin of -157.53%. MiNK Therapeutics' return on equity of 0.00% beat Future FinTech Group's return on equity.

Company Net Margins Return on Equity Return on Assets
MiNK TherapeuticsN/A N/A -103.82%
Future FinTech Group -157.53%-12.22%-10.08%

Future FinTech Group has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Future FinTech Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiNK TherapeuticsN/AN/A-$12.49M-$2.25N/A
Future FinTech Group$3.83M7.83-$4.62M-$30.16N/A

MiNK Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Future FinTech Group has a beta of 1.72, indicating that its share price is 72% more volatile than the broader market.

MiNK Therapeutics presently has a consensus target price of $44.00, suggesting a potential upside of 374.14%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe MiNK Therapeutics is more favorable than Future FinTech Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiNK Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Future FinTech Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

MiNK Therapeutics beats Future FinTech Group on 9 of the 14 factors compared between the two stocks.

How does MiNK Therapeutics compare to Cartesian Therapeutics?

Cartesian Therapeutics (NASDAQ:RNAC) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Cartesian Therapeutics currently has a consensus target price of $32.60, indicating a potential upside of 432.68%. MiNK Therapeutics has a consensus target price of $44.00, indicating a potential upside of 374.14%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Cartesian Therapeutics is more favorable than MiNK Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cartesian Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
MiNK Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

In the previous week, MiNK Therapeutics had 12 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 15 mentions for MiNK Therapeutics and 3 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.70 beat MiNK Therapeutics' score of 0.53 indicating that Cartesian Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cartesian Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
MiNK Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

87.0% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by company insiders. Comparatively, 20.4% of MiNK Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cartesian Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market.

MiNK Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%.

Company Net Margins Return on Equity Return on Assets
Cartesian Therapeutics-8,550.65% N/A -23.63%
MiNK Therapeutics N/A N/A -103.82%

MiNK Therapeutics has lower revenue, but higher earnings than Cartesian Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cartesian Therapeutics$2.80M66.66-$130.30M-$4.94N/A
MiNK TherapeuticsN/AN/A-$12.49M-$2.25N/A

Summary

Cartesian Therapeutics beats MiNK Therapeutics on 9 of the 13 factors compared between the two stocks.

How does MiNK Therapeutics compare to Eledon Pharmaceuticals?

MiNK Therapeutics (NASDAQ:INKT) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

MiNK Therapeutics' return on equity of 0.00% beat Eledon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
MiNK TherapeuticsN/A N/A -103.82%
Eledon Pharmaceuticals N/A -160.61%-55.54%

MiNK Therapeutics presently has a consensus price target of $44.00, indicating a potential upside of 374.14%. Eledon Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 405.05%. Given Eledon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than MiNK Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiNK Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Eledon Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiNK TherapeuticsN/AN/A-$12.49M-$2.25N/A
Eledon PharmaceuticalsN/AN/A-$45.62M-$0.73N/A

MiNK Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

In the previous week, MiNK Therapeutics had 9 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 15 mentions for MiNK Therapeutics and 6 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.55 beat MiNK Therapeutics' score of 0.53 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MiNK Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Eledon Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Summary

Eledon Pharmaceuticals beats MiNK Therapeutics on 7 of the 11 factors compared between the two stocks.

How does MiNK Therapeutics compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Pyxis Oncology presently has a consensus price target of $8.71, suggesting a potential upside of 505.16%. MiNK Therapeutics has a consensus price target of $44.00, suggesting a potential upside of 374.14%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, research analysts clearly believe Pyxis Oncology is more favorable than MiNK Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pyxis Oncology
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75
MiNK Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

In the previous week, MiNK Therapeutics had 15 more articles in the media than Pyxis Oncology. MarketBeat recorded 15 mentions for MiNK Therapeutics and 0 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.61 beat MiNK Therapeutics' score of 0.53 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company Overall Sentiment
Pyxis Oncology Positive
MiNK Therapeutics Positive

Pyxis Oncology has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are held by institutional investors. 10.5% of Pyxis Oncology shares are held by insiders. Comparatively, 20.4% of MiNK Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MiNK Therapeutics' return on equity of 0.00% beat Pyxis Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Pyxis OncologyN/A -252.36% -120.63%
MiNK Therapeutics N/A N/A -103.82%

MiNK Therapeutics has lower revenue, but higher earnings than Pyxis Oncology. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pyxis Oncology$13.86M12.43-$79.62M-$1.30N/A
MiNK TherapeuticsN/AN/A-$12.49M-$2.25N/A

Summary

Pyxis Oncology beats MiNK Therapeutics on 8 of the 13 factors compared between the two stocks.

How does MiNK Therapeutics compare to BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

BridgeBio Oncology Therapeutics has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

MiNK Therapeutics' return on equity of 0.00% beat BridgeBio Oncology Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BridgeBio Oncology TherapeuticsN/A -49.01% -43.18%
MiNK Therapeutics N/A N/A -103.82%

MiNK Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Oncology TherapeuticsN/AN/A-$134.04M-$2.16N/A
MiNK TherapeuticsN/AN/A-$12.49M-$2.25N/A

54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are owned by insiders. Comparatively, 20.4% of MiNK Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, MiNK Therapeutics had 9 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 15 mentions for MiNK Therapeutics and 6 mentions for BridgeBio Oncology Therapeutics. MiNK Therapeutics' average media sentiment score of 0.53 beat BridgeBio Oncology Therapeutics' score of 0.46 indicating that MiNK Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Oncology Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
MiNK Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

BridgeBio Oncology Therapeutics presently has a consensus price target of $19.33, suggesting a potential upside of 896.56%. MiNK Therapeutics has a consensus price target of $44.00, suggesting a potential upside of 374.14%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than MiNK Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Oncology Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82
MiNK Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Summary

BridgeBio Oncology Therapeutics beats MiNK Therapeutics on 8 of the 12 factors compared between the two stocks.

Get MiNK Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INKT vs. The Competition

MetricMiNK TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$48M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E RatioN/A26.7134.3428.32
Price / SalesN/A15.788.495.70
Price / CashN/A22.9521.0121.90
Price / Book-2.934.184.453.72
Net Income-$12.49M-$24.15M$3.52B$393.10M
7 Day Performance-9.20%-7.81%-5.93%-5.77%
1 Month Performance-1.38%-5.99%-4.58%-7.14%
1 Year Performance-17.95%-8.09%-1.94%-7.46%

MiNK Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INKT
MiNK Therapeutics
2.6884 of 5 stars
$9.28
-0.7%
$44.00
+374.1%
-22.7%$48MN/AN/A15
FTFT
Future FinTech Group
0.4014 of 5 stars
$4.10
+1.5%
N/A-95.0%$35.05M$3.83MN/A32
RNAC
Cartesian Therapeutics
1.959 of 5 stars
$6.35
-0.2%
$32.60
+413.4%
-17.1%$193.85M$2.80MN/A75
ELDN
Eledon Pharmaceuticals
1.7465 of 5 stars
$2.12
-10.5%
$10.00
+371.7%
+22.2%$192.18MN/AN/A33
PYXS
Pyxis Oncology
2.6154 of 5 stars
$1.58
flat
$8.71
+451.5%
-69.0%$188.98M$13.86MN/A56

Related Companies and Tools


This page (NASDAQ:INKT) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners